18/The phase 3 SEQUOIA-HCM trial found that an investigational CMI—aficamten—for 24 weeks resulted in significantly greater improvement in pVO2 than placebo (least-squares mean between-group difference, 1.7 mL/kg/min; 95% CI, 1.0 to 2.4; P < .001).

19/Thank you for joining this #CME activity!
To earn CME credit or view references: clinical.med-iq.com/activity/1889

Interested in more on this topic? View the ACC CardiaCast: www.acc.org/Latest-in-Ca...